“At Moderna, we have several different modalities that we’re working towards,” she said. “We’ve proven our approach works with infectious diseases, so there’s a really big focus on that — but I think we can also go way beyond.
“We look forward to working together and exploring how we can leverage the varied expertise and capabilities that exist at the University of Toronto. We’re excited to share more about our research priorities going forward — and to hear your thoughts on how U of T investigators and teams from different disciplines can be pulled together to tackle complex problems and contribute to improving the lives of patients around the world.”
Omar Khan, an assistant professor at U of T’s Institute of Biomedical Engineering, was among the university researchers who attended a Moderna presentation delivered by Andrea Carfi, the company’s chief scientific officer, infectious diseases. Khan, whose lab is creating new nanotechnologies to control and deliver nucleic acids, will lead a team that plans on working with Moderna to develop next-generation vaccine platforms.
“The pandemic has showed us how innovation in the nucleic acid delivery space can result in great things,” said Khan, who holds a Canada Research Chair in Nucleic Acid Therapeutics.
“There are still so many opportunities to create technologies that protect people from other diseases.”